Aradigm inks development pact with Grifols

Tweet Grifols (NASDAQ:GRFS) of Spain and Aradigm (OTCBB:ARDM) have signed an exclusive, worldwide license for Aradigm’s proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase 2b clinical trials in BE patients with Pulmaquin and Lipoquin. Under the accord, the companies [...]

Medigus to present three-year follow-up data of SRS pivotal study at DDW

Tweet Medigus (TASE:MDGS) will be presenting the successful three-year follow-up data of the SRS pivotal study at the Digestive Disease Week in Orlando on May 18 to 21. The study, conducted at Indiana University, clearly indicates that the majority of patients treated by Medigus’ endoscopic system SRS were able to stop taking daily PPl (drugs [...]

2nd Annual Bloom Burton & Co. Healthcare Investor Conference; we’ll be there

Tweet Bloom Burton & Co., Canada’s largest and most active healthcare-specialized investment banking group, is hosting its 2nd Annual Healthcare Investor Conference on Wednesday, May 22 at the Toronto Board of Trade, 1 First Canadian Place, Toronto. This conference brings together brings together U.S., Canadian and international investors who are interested in the latest developments in the [...]

TearLab Q1 revenue jumps 486%

Tweet First quarter revenue for TearLab (NASDAQ:TEAR; TSX:TLB) rose 486% to $2.5-million from $422,000 a year ago, and was up 54% sequentially from $1.6-million in the fourth quarter of 2012.  The company reported an adjusted net loss of $0.11 per share, beating consensus analyst estimates by a cent. A total of 388 orders for TearLab [...]

Cynapsus names Dexcel execs to its board

Tweet Tomer Gold, VP of R&D, of closely-held Dexcel Pharma, and Ilan Oren, VP of business development at Dexcel, have joined the board of Cynapsus Therapeutics (TSX-V:CTH). Dexcel recently acquired 7,608,696 units of Cynapsus for $3.5-million, resulting in a 19.6% and 24% holding of Cynapsus outstanding stock on a basic and fully diluted basis, respectively. [...]

Feltl analyst highlights Novadaq and TearLab in WSJ interview

Tweet The Wall Street Journal has announced its 2012 “Best On The Street” stock picker rankings, with Feltl analyst, Ben Haynor, coming second in the Medical Equipment & Supplies category. In an interview with the WSJ, Mr. Haynor called Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) his “best call” during 2012 and said TearLab (NASDAQ:TEAR; TSX:TLB) is the [...]

Orgenesis and ATMI in process development accord

Tweet Orgenesis (OTCBB:ORGS) has entered into a process development agreement with ATMI (NASDAQ:ATMI), a global technology company and leader in single-use bioprocess solutions. Under the accord, ATMI will supply Orgenesis with a complete disposable manufacturing process for the expansion of a patient’s liver cells outside of the body, an important step in Orgenesis’ therapeutic technology [...]

Oramed readies oral insulin study in U.S.

Tweet Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a large, multi-center Phase 2 clinical trial later this year. “Approving a clinical trial in the U.S. for oral insulin is a big deal,” [...]

William Blair starts Chimerix at outperform

Tweet William Blair & Co. has initiated coverage of Chimerix (NASDAQ:CMRX) with an “outperform” rating and $28 price target. The stock was quoted at $20.82 on Monday afternoon. Chimerix has produced two clinical antiviral candidates employing its proprietary lipid-conjugation technology. The novel antivirals have much enhanced efficacy and safety profiles, compared with the original unconjugated [...]

Byron Capital ups Cipher price target

Tweet Byron Capital Markets has raised its price target on “buy-rated” Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) to $6.25 from $5.25, after the company posted record results for the first quarter. The stock closed at $3.80 on Friday. “Our key takeaway is the Absorica launch is outperforming even our optimistic expectations,” writes analyst Doug Loe. On Absorica’s [...]

Next Page »